Swedish Orphan Biovitrum AB (publ) Analysts See $0.21 EPS as of July, 18

June 27, 2018 - By Kevin Carney

Swedish Orphan Biovitrum AB (OTCMKTS:publ) Corporate Logo

Investors wait Swedish Orphan Biovitrum AB (OTCMKTS:publ)’s quarterly earnings on July, 18., Faxor reports. If $0.21 is reported, SWTUY’s profit will hit $57.46M for 25.65 P/E. -12.50 % negative EPS growth is what Wall Street’s sees after $0.24 reported EPS last quarter. Ticker’s shares touched $21.55 during the last trading session after 2.36% change.Swedish Orphan Biovitrum AB has 965 shares volume, 315.95% up from normal. publ is and has moved 0.00% since June 27, 2017. publ underperformed by 12.57% the S&P 500.

Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, makes, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Sweden and internationally.The company has $5.90 billion market cap. The Company’s core products include Kineret for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease; Orfadin for the treatment of hereditary tyrosinaemia type 1 genetic disorder; and Xiapex for the treatment of Dupuytren's contracture and Peyronie's disease.35.5 is the P/E ratio. The firm also offers Elocta and Alprolix for the treatment of haemophilia; and Ammonaps, Ammonul, and Ravicti for use in the genetics and metabolism diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: